Role of Charlson cormobidity index in the advanced non small cell lung cancer

H. Ooi, Y. T. Wang, Y. H. Liu, T. C. Hsia, C. M. Shih, W. H. Hsu (Taichung, Taiwan, Province Of China)

Source: Annual Congress 2006 - Biology and prognostic factors
Session: Biology and prognostic factors
Session type: Poster Discussion
Number: 2284

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
H. Ooi, Y. T. Wang, Y. H. Liu, T. C. Hsia, C. M. Shih, W. H. Hsu (Taichung, Taiwan, Province Of China). Role of Charlson cormobidity index in the advanced non small cell lung cancer. Eur Respir J 2006; 28: Suppl. 50, 2284

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Impact of poor performance status of the treatment of small cell lung cancer
Source: Eur Respir J 2001; 18: Suppl. 33, 394s
Year: 2001

A modified ILD-GAP index for patients with non-small cell lung cancer and interstitial lung disease
Source: International Congress 2018 – Lung cancer: personalised medicine
Year: 2018



Quality indicators in lung cancer care-review of resection rates in early stage NSCLC (non small cell lung cancer) at King’s
Source: International Congress 2018 – Lung cancer: risk factors, supportive measures and quality improvement
Year: 2018

Prognostic value of comorbidity in operated non-small cell lung cancer
Source: Eur Respir J 2006; 28: Suppl. 50, 763s
Year: 2006

Prognostic value of smoking status in operated non-small cell lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 40s
Year: 2004

Assessment of comorbidity in newly diagnosed lung cancer patients
Source: Annual Congress 2009 - Clinical aspects and epidemiology in lung cancer
Year: 2009

Rates of treatment response and median survival in advanced non small cell lung cancer patients
Source: Eur Respir J 2004; 24: Suppl. 48, 302s
Year: 2004

Symptom control in advanced non-small cell lung cancer (NSCLC): what is the influence of cisplatin-use, age, performance status and duration of chemotherapy? Analysis of a randomized database
Source: Eur Respir J 2002; 20: Suppl. 38, 596s
Year: 2002

Effect of comorbidity on the prognosis of non-small cell lung cancer
Source: Eur Respir J 2006; 28: Suppl. 50, 385s
Year: 2006

Comorbidity in lung cancer – operated patients. Impact on survival and prognosis
Source: Eur Respir J 2005; 26: Suppl. 49, 327s
Year: 2005

Comorbidity in lung cancer patients
Source: Annual Congress 2010 - Best supportive care and palliation for lung cancer patients
Year: 2010

Prognostic implications of smoking in patients with advanced lung adenocarcinoma excluding positive mutations
Source: International Congress 2016 – Prognostic variables in lung cancer I
Year: 2016


Prognostic value of apoptotic index in non-small cell lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 5s
Year: 2004

Importance of weight loss definition in the prognostic evaluation of nonsmall cell lung cancer
Source: Eur Respir J 2001; 18: Suppl. 33, 477s
Year: 2001

Comorbidity related to age and gender in lung cancer patients
Source: Eur Respir J 2007; 30: Suppl. 51, 670s
Year: 2007

Chemotherapy in advanced non small cell lung cancer
Source: Eur Respir J 2005; 26: Suppl. 49, 77s
Year: 2005

Lung cancer: does age affect treatment strategy?
Source: Eur Respir Mon; 2009: 43:306–326
Year: 2009

Impacts of multi and specific co-morbidities on the survival of non-surgical non-small cell lung cancer
Source: Annual Congress 2012 - Prognosis of lung cancer
Year: 2012

Potential diagnostic markers in bronquial fluid of patients with non small cell lung cancer (NSCLC)
Source: Annual Congress 2009 - Biological and clinical markers in lung cancer
Year: 2009